YLYongjiang Li

Yongjiang Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yongjiang Li has a total of 176 co-authors. Here are the top co-authors by number of shared publications:

  • Da-Xiong Xiang

    Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, 410011, China

    13 shared publications
  • Jun-Yong Wu

    Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People’s Republic of China

    12 shared publications
  • Jie-Min Wang

    Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China

    9 shared publications
  • Wei Tao

    Department of Pharmacology Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore

    6 shared publications
  • Xiong-Bin Hu

    Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China

    6 shared publications
  • Wei Chen

    Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA

    5 shared publications

Latest Publications

  • Bioactive lipid-derived nanoparticles for RNA delivery

    by Kaiqi Long, Jeffrey Yuan, Yang Zhang, Yongjiang Li, Minling Zhong, Weiping Wang, Jinjun Shi

  • Open Access

    Reprogramming Lesional Macrophage Homeostasis via Interferon Regulatory Factor 5 Targeted siRNA Nanoimmunotherapy for Atherosclerosis

    by Zhongshan He, Yaoyao Luo, Shuping Yang, Haixing Shi, Ya-Chih Huang, Zhuoming Zhou, Shengbin Liu, Wanqin Zeng, Wei-Chieh Liu, Yongjiang Li, et al.

    Atherosclerotic macrophages predominantly exhibit a pro-inflammatory phenotype, driving chronic inflammatory and accelerating atherosclerotic progression. Interferon regulatory factor 5 (IRF5) is highly expressed in lesional macrophages within advanced atherosclerotic plaques, where it promotes the secretion of pro-inflammatory cytokines. However, current approaches lack an effective therapeutic strategy to specifically silence this gene in lesional macrophages for atherosclerosis treatment. This study aims to develop and evaluate a dual-targeted, siRNA-based nanotherapeutic platform that selectively acts on atherosclerosis-promoting genes in plaque macrophages, offering a potential strategy for treating atherosclerosis by reprogramming lesional macrophages. Here we designed and developed dual-targeted liposome-based nano-immunotherapeutics encapsulating small interfering RNA (siRNA) against IRF5 (siIRF5) to reprogram macrophage phenotypes within advanced plaques. In high-fat diet-fed ApoE-/- mice with advanced atherosclerotic plaques, dual-targeted siIRF5-loaded liposomes effectively accumulate within lesional macrophages, downregulate IRF5 expression, and promote anti-inflammatory macrophage polarization. Moreover, this siIRF5-based nanoimmunotherapy significantly reduces plaque burden and enhances plaque stability in two independent murine models of atherosclerosis. Furthermore, this siIRF5 nanoimmunotherapy exhibits biocompatibility even after long-term administration, underscoring its translational potential for clinical application in atherosclerosis treatment. This study introduces an innovative dual-targeted siRNA-based nanotherapeutic strategy that acts on atherosclerosis-promoting genes in plaque macrophages, offering a promising therapeutic avenue for atherosclerosis and other macrophage-driven inflammatory diseases.


  • IRF5 siRNA Nanoimmunotherapy: Restoring Macrophage Efferocytosis in Atherosclerosis

    by Zhongshan He, Yaoyao Luo, Zhonghui Duan, Bin Su, Wanqin Zeng, Yu Guo, Yongjiang Li, Xi He, Haixing Shi, Zhuoming Zhou, et al.

    BACKGROUND: Impaired efferocytosis of macrophages within advanced atherosclerotic plaques leads to plaque deposition and rupture, ultimately resulting in atherothrombotic events. Effective restoration of efferocytic capacity in lesional macrophages remains a challenge in atherosclerosis treatment. METHODS: We developed an engineered small interfering RNA (siRNA) nanoparticle platform that can therapeutically manipulate lesional macrophages by inhibiting an overexpressed plaque-destabilizing macrophage molecule: IRF5 . RESULTS: IRF5 siRNA (siIRF5) nanoimmunotherapeutics were efficiently taken up by lesional macrophages, particularly Cd11c + and Trem2 hi macrophages, and enhanced their phagocytic clearance of apoptotic cells by efficiently silencing IRF5 expression within these macrophage subsets in atherosclerotic plaques. This resulted in remarkable therapeutic efficacy, as evidenced by reduction of necrotic core area and enhancement of plaque stability in 2 independent ApoE −/− murine models of atherosclerosis. Single-cell RNA sequencing analysis revealed that siIRF5 nanoimmunotherapeutics increased the proefferocytic receptors while decreasing the expression of proinflammatory genes associated with cytokine and chemokine pathways in lesional macrophages. CONCLUSIONS: These findings highlight the potential of siRNA nanoimmunotherapeutics for treating atherosclerosis and other diseases resulting from impaired efferocytosis in macrophages.


  • Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease

    by Xiangang Huang, Chuang Liu, Shonit Nair Sharma, Xinru You, Shuying Chen, Yongjiang Li, Hai-Jun Liu, Bin Liu, Qimanguli Saiding, Wei Chen, et al.

    Oral delivery of messenger RNA (mRNA) therapeutics could offer noninvasive and self-administered treatments and vaccinations. However, the development of oral mRNA therapeutics remains challenging because of the degradative conditions of the gastrointestinal (GI) tract. Here, we engineered a capsule-based device, named RNACap, designed for oral delivery of liquid mRNA nanoparticle (NP) therapeutics to the intestines. RNACap protects mRNA from the acidic stomach environment while allowing rapid release into the intestines in response to intestinal neutral pH, pressure release due to the dissolution of capsule cap, and natural intestinal contractions (peristalsis). This process enables NP-mediated delivery of mRNA into intestinal cells for in vivo transfection. We optimized an NP formulation for rapid intestinal mRNA delivery. In rat and porcine models, we confirmed that the RNACap remains intact in the stomach but releases its contents within the intestines. The release of mRNA NPs led to the expression of multiple mRNAs. The therapeutic effect of the RNACap was demonstrated by acute and delayed treatment in two rat colitis models. Orally administered RNACaps loaded with mRNA encoding interleukin-10 ( IL-10 mRNA NP) reduced proinflammatory cytokine concentrations in both blood and tissues, ultimately alleviating colitis. Furthermore, using a large-animal model of swine, we showed that RNACaps remained intact in the stomach, disassembled in the intestine, and resulted in robust mRNA expression just 8.5 hours after administration. RNACap represents a promising platform for the oral delivery of liquid mRNA therapeutics to the GI tract for treating challenging intestinal diseases and potentially other conditions.


  • Open Access

    Synthetic carbon-based lanthanide upconversion nanoparticles for enhanced photothermal therapy

    by Mei Yang, Yida Huang, Zhongxing Chen, Qianfang Ye, Zhenhai Zeng, Xinru You, Bijun Bao, Wenqian Xing, Nan Zhao, Zhilin Zou, et al.

    Photothermal therapy (PTT), a vanguard strategy in cancer/ocular neovascularization treatment, has attracted considerable attention owing to its precision, controllability, high efficacy, and minimal side effects. Nevertheless, its inherent limitations necessitate innovative solutions. One promising strategy is to develop reagents with enhanced photothermal conversion efficiency under long-wavelength laser irradiation. Carbon nanomaterials, known for their broad absorption spectra, are currently hindered by single-wavelength lasers in clinical treatments. In this study, we address this limitation by coating mesoporous carbon nanomaterials (MCNs) with a lanthanide oxysulfide up-conversion material (Y2O2S:Yb3+,Er3+), converting 980 nm light into visible light. This advancement enhances the photothermal conversion efficiency of the produced MCNs/Ln/GD/FR nanocomposites from 59.48% to 82.86%. Furthermore, the incorporation of gambogic acid and doxorubicin intensifies the synergistic photothermal therapy effect. A dual stimuli-responsive hydrogel (PNIPAM) is employed to ensure controlled drug release and safe delivery to tumors. Evaluations demonstrate that the MCNs/Ln/GD/FR nanocomposites exhibit exceptional tumor targeting and evident photothermal synergistic therapy effects on both subcutaneous and ocular in situ melanoma tumors by activating tumor-suppressive signaling pathways while inhibiting proliferation and differentiation-related pathways. These findings might pave the way for the development of photothermal reagent and offer valuable insights for advancing therapeutic strategies.


  • Top Cited Papers
    Open Access

    Macrophage hitchhiking nanomedicine for enhanced β-elemene delivery and tumor therapy

    by Shuying Chen, Yongjiang Li, Zhuoming Zhou, Qimanguli Saiding, Yiming Zhang, Soohwan An, Muhammad Muzamil Khan, Xiaoyuan Ji, Ruirui Qiao, Wei Tao, et al.

    Nanoparticle-based drug delivery systems hold promise for tumor therapy; however, they frequently encounter challenges such as low delivery efficiency and suboptimal efficacy. Engineered living cells can redirect drug delivery systems to effectively reach targeted sites. Here, we used living macrophages as vehicles, attaching them with GeS nanosheets (GeSNSs) carrying β-elemene for transport to tumor sites. GeSNSs act as efficient sonosensitizers, enhancing ultrasound-induced reactive oxygen species generation for treating 4T1 breast tumors. Notably, macrophage hitchhiking delivery of β-elemene–loaded GeSNSs not only achieves high accumulation in tumor regions and suppresses tumor growth under ultrasound treatment, but also effectively remodels the immunosuppressive tumor microenvironment by improving M1-like macrophage polarization and enhancing the populations of mature dendritic cells, CD4 + , and CD8 + lymphocytes, thereby facilitating enhanced sonodynamic chemoimmunotherapy. These findings underscore the potential of macrophage hitchhiking strategy for drug delivery and suggest broader applicability of engineered living materials–mediated delivery technologies in disease therapy.


  • Open Access

    Biomimetic Self-Oxygenated Immunoliposome for Cancer-Targeted Photodynamic Immunotherapy

    by Yucheng Tang, Tiantian Tang, Yongjiang Li, Junyong Wu, Xinyi Liu, Daxiong Xiang, Xiongbin Hu

    Objective: Photodynamic therapy (PDT) is a promising strategy with significant clinical application potential for tumor treatment. However, the tumor hypoxia and limited efficacy against tumor metastasis present significant limitations in the clinical application of PDT. To alleviate tumor hypoxia for PDT against tumor growth and metastasis, we developed a self-oxygenated immunoliposome by encapsulating the catalase (CAT) within the liposome cavity and loading the photosensitizer chlorin e6 (Ce6) and immunoadjuvant MPLA in the lipid bilayer of the immunoliposome (CAT@LP-Ce6-A). Subsequently, we fused it with the cancer cell membrane (CCM) to create the hybrid immunoliposome (CAT@LP-CCM-Ce6-A). The in vitro and in vivo anti-cancer efficacy of CAT@LP-CCM-Ce6-A-based photodynamic immunotherapy (PDIT) was evaluated. Methods: CAT@LP-CCM-Ce6-A were characterized by size, zeta potential, transmission electron microscopy (TEM), Coomassie bright blue staining, UV spectrophotometer, and standard Goth’s method. Cellular uptake, cell viability, reactive oxygen species (1O2) generation, calreticulin exposure, and ability to promote BMDCs maturation of CAT@LP-CCM-Ce6-A were evaluated in vitro. Biodistribution, anti-cancer therapeutic efficacy, and in vivo safety of CAT@LP-CCM-Ce6-A were investigated in orthotopic triple-negative breast cancer (TNBC) lung metastasis mouse models. Results: CAT@LP-CCM-Ce6-A was successfully developed via the thin film hydration and co-extrusion method. The loading capacity of Ce6 and CAT was 4.7 ± 0.9% and 8.5 ± 0.9% respectively. CAT@LP-CCM-Ce6-A exhibited improved cellular uptake efficiency and cytotoxicity under laser irradiation against TNBC. Furthermore, CAT@LP-CCM-Ce6-A possessed enhanced anti-enzymatic degradation ability and promotion of DC maturation. In TNBC-bearing mice, CAT@LP-CCM-Ce6-A-based PDIT demonstrated remarkable therapeutic effect and antitumor immunity while maintaining minimal systemic toxicity. Conclusion: CAT@LP-CCM-Ce6-A could be employed as an innovative approach for self-oxygenated photodynamic immunotherapy against cancer.


  • One-Pot Synthesis of Fe-Norepinephrine Nanoparticles for Synergetic Thermal-Enhanced Chemodynamic Therapy

    by Yufen Xiao, Zhongmin Tang, Jiamin Zhang, Qimanguli Saiding, Yongjiang Li, Jianzhong Du, Wei Tao

    Chemodynamic therapy (CDT) is an innovative and burgeoning strategy that utilizes Fenton-Fenton-like chemistry and specific microenvironments to produce highly toxic hydroxyl radicals (•OH), with numerous methods emerging to refine this approach. Herein, we report a coordination compound, Fe-norepinephrine nanoparticles (Fe-NE NPs), via a one-pot synthesis. The Fe-NE NPs are based on ferrous ions (Fe2+) and norepinephrine, which are capable of efficient Fe2+/Fe3+ delivery. Once internalized by tumor cells, the released Fe2+/Fe3+ exerts the Fenton reaction to specifically produce toxic •OH. Moreover, the internal photothermal conversion ability of Fe-NE NPs allows us to simultaneously introduce light to trigger local heat generation and then largely improve the Fenton reaction efficiency, which enables a synergetic photothermal and chemodynamic therapy to realize satisfactory in vivo antitumor efficiency. This proof-of-concept work offers a promising approach to developing nanomaterials and refining strategies for enhanced CDT against tumors.


  • Top Cited Papers

    Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment

    by Zhongshan He, Wei Chen, Kuan Hu, Yaoyao Luo, Wanqin Zeng, Xi He, Tingting Li, Jiang Ouyang, Yongjiang Li, Lin Xie, et al.

    The buildup of plaques in atherosclerosis leads to cardiovascular events, with chronic unresolved inflammation and overproduction of reactive oxygen species (ROS) being major drivers of plaque progression. Nanotherapeutics that can resolve inflammation and scavenge ROS have the potential to treat atherosclerosis. Here we demonstrate the potential of black phosphorus nanosheets (BPNSs) as a therapeutic agent for the treatment of atherosclerosis. BPNSs can effectively scavenge a broad spectrum of ROS and suppress atherosclerosis-associated pro-inflammatory cytokine production in lesional macrophages. We also demonstrate ROS-responsive, targeted-peptide-modified BPNS-based carriers for the delivery of resolvin D1 (an inflammation-resolving lipid mediator) to lesional macrophages, which further boosts the anti-atherosclerotic efficacy. The targeted nanotherapeutics not only reduce plaque areas but also substantially improve plaque stability in high-fat-diet-fed apolipoprotein E-deficient mice. This study presents a therapeutic strategy against atherosclerosis, and highlights the potential of BPNS-based therapeutics to treat other inflammatory diseases.


  • Open Access

    Modification of contact lenses via metal‐organic frameworks for glaucoma treatment

    by Alexey V. Yaremenko, Roman O. Melikov, Nadezhda A. Pechnikova, Iaroslav B. Belyaev, Alina Ringaci, Tamara V. Yaremenko, Aziz B. Mirkasymov, Alexandr A. Tamgin, Vladislav I. Rodionov, Sofya M. Dolotova, et al.

    The prevention of blindness from glaucoma requires multiple treatments to lower intraocular pressure. Here, human contact lenses are modified with highly porous metal‐organic frameworks with sustained release of brimonidine for prolonged glaucoma treatment. Various metal‐organic frameworks were screened for their attachment to lenses, loading with brimonidine, and drug‐release properties. Optimized therapeutic ocular lenses conjugated with MIL‐101(Cr) frameworks maintain optical transparency and power. Coating of lenses with MIL‐101(Cr) nanoparticles reduced brimonidine washout with tears and ensured a gradual and localized release of the drug into the eyeball through the cornea. The hybrid lenses provided a 4.5‐fold better decrease in eye pressure, compared by area under the curve (AUC) value to a commercially available brimonidine tartrate solution. Therapeutic lenses did not induce any notable eye irritation or corneal damage in vivo. The newly developed hybrid lenses are expected to provide a robust platform for the therapy and prevention of various ocular diseases.